z-logo
open-access-imgOpen Access
Role of Vpma phase variation in M ycoplasma agalactiae pathogenesis
Author(s) -
ChopraDewasthaly Rohini,
Baumgartner Martina,
Gamper Erika,
Innerebner Carmen,
Zimmermann Martina,
Schilcher Franz,
Tichy Alexander,
Winter Petra,
Jechlinger Wolfgang,
Rosengarten Renate,
Spergser Joachim
Publication year - 2012
Publication title -
fems immunology & medical microbiology
Language(s) - English
Resource type - Journals
eISSN - 1574-695X
pISSN - 0928-8244
DOI - 10.1111/j.1574-695x.2012.01010.x
Subject(s) - biology , phase variation , antigenic variation , virulence , mycoplasma , microbiology and biotechnology , pathogen , immune system , pathogenesis , pathogenicity island , genetics , virology , immunology , gene
Compared with other bacterial pathogens, the molecular mechanisms of mycoplasma pathogenicity are largely unknown. Several studies in the past have shown that pathogenic mycoplasmas are equipped with sophisticated genetic systems that allow them to undergo high‐frequency surface antigenic variations. Although never clearly proven, these variable mycoplasma surface components are often implicated in host immune evasion and adaptation. Vpma surface lipoproteins of the ruminant pathogen M ycoplasma agalactiae are encoded on a genomic pathogenicity island–like locus and are considered as one of the well‐characterized model systems of mycoplasma surface antigenic variation. The present study assesses the role of these phase‐variable Vpmas in the molecular pathogenesis of M . agalactiae by testing the wild‐type strain PG 2 in comparison with the xer1 ‐disrupted Vpma ‘phase‐locked’ mutants in sheep infection models. The data clearly illustrate that although Xer1 recombinase is not a virulence factor of M . agalactiae and Vpma phase variation is not necessary for establishing an infection, it might critically influence the survival and persistence of the pathogen under natural field conditions, mainly due to a better capacity for dissemination and evoking systemic responses. This is the first study where mycoplasma ‘phase‐locked’ mutants are tested in vivo to elucidate the role of phase variation during infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here